828934-72-1

Upstream product

• 749913-58-4 4-(2,5-difluoro-benzyl)-1-(1,4-dioxa-spiro[4.5]dec-8-yl)-piperidine 
• 749913-60-8 4-[4-(2,5-difluoro-benzyl)-piperidin-1-yl]-cyclohexanone 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 90049-79-9 4-isocyanato-benzo[1,3]dioxole 
• 749913-62-0 {4-[4-(2,5-difluoro-benzyl)-piperidin-1-yl]-cyclohex-1-enyl}-dimethyl-amine 

Relevant academic research and scientific papers

Ligand conformation has a definitive effect on 5-HT1A and serotonin reuptake affinity

Conformationally constrained cyclohexanes and cyclohexenes were prepared and tested for 5-HT1A and SSRI activity. The conformation of the dioxyaryl ring with respect to the cyclohexane ring is a key factor for selecting the relative potency of the compounds at the two receptors studied. Conformationally constrained aryl cyclohexanes and cyclohexenes based on aryl cyclohexanols 1 were prepared. Locking the aryl ring in plane with the cyclohexane moiety provided potent SSRIs 3. Conversely, fixing the aryl ring perpendicular to the cyclohexane ring via a spiro lactone provided balanced 5-HT1A antagonists with mid-nanomolar range SSRI potency (compounds 2).